MISSISSAUGA, Ontario, June 12, 2014 (GLOBE NEWSWIRE) -- via PRWEB - Canadian Business and PROFIT today ranked Therapure Biopharma Inc. in the top 5% of the fastest growing Canadian companies on the 26th annual PROFIT 500 list. Published in the July issue of Canadian Business and online at PROFITguide.com, the PROFIT 500 ranks Canadian businesses by their revenue growth over five years.
"The members of the PROFIT 500 are the elite of the country's entrepreneurial community," says James Cowan, Editor-in-Chief of Canadian Business and PROFIT. "Their stories are lessons in business strategy, innovation, management excellence and sheer tenacity."
"Therapure is honoured to be in the PROFIT 500 ranking," says Therapure President and CEO, Nick Green. "I am especially proud of our employees and our investors in that they have made such impressive performance possible. Our growth is based on a strong foundation of therapeutic protein manufacturing expertise, and it is supported by the enormous commitment, passion, and innovative thinking of our highly talented team. While not a factor in our current growth, I am equally proud of and excited by the advancement of our product development programs that offer significant promise for the future treatment of liver cancer, anemia and other unmet medical needs," says Green.
Since its entry into the Contract Development and Manufacturing Organization (CDMO) space in 2008, Therapure has achieved impressive growth, which includes the execution of more than thirty service contracts for developing and manufacturing biologic drugs with a broad spectrum of Canadian and international customers.
Therapure's capabilities and expertise include cell line development, upstream and downstream process development, cGMP manufacturing for preclinical, clinical and commercial drug supply and aseptic fill/finish of injectable drugs. These integrated services and talented employees have positioned Therapure to successfully compete in the global biomanufacturing sector.
About PROFIT and PROFITguide.com
PROFIT: Your Guide to Business Success is Canada's preeminent media brand dedicated to the management issues and opportunities facing small and mid-sized businesses. For 32 years, Canadian entrepreneurs across a vast array of economic sectors have remained loyal to PROFIT because it's a timely and reliable source of actionable information that helps them achieve business success and get the recognition they deserve for generating positive economic and social change. Visit PROFIT online at PROFITguide.com.
About Canadian Business
Founded in 1928, Canadian Business is the longest-serving, best-selling and most-trusted business publication in the country. With a readership of more than 800,000, it is the country's premier media brand for executives and senior business leaders. It fuels the success of Canada's business elite with a focus on the things that matter most: leadership, innovation, business strategy and management tactics. We provide concrete examples of business achievement, thought-provoking analysis and compelling storytelling, all in an elegant package with bold graphics and great photography. Canadian Business--what leadership looks like.
About Therapure Biopharma Inc.
Therapure Biopharma Inc. is a multiple award-winning biopharmaceutical company focused on complex biological therapeutics and technologies. It is composed of Therapure Biomanufacturing, the contract development and manufacturing division, and Therapure Innovations, the proprietary therapeutics and platform technologies research and development division. Therapure Biopharma Inc.'s flexible, state-of-the-art, 130,000 sq. ft. facility, located in Mississauga, Ontario, includes research laboratories, cGMP biomanufacturing and aseptic fill/finish suites, as well as quality control laboratories built to meet FDA (USA), HPFB (Canada) and EMA (Europe) standards.
For more information, please visit: http://www.therapurebio.com.
Company Contact:
Dina Iezzi
Director, Marketing and Special Projects
diezzi(at)therapurebio(dot)com
(905) 286-6270
This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2014/06/prweb11939377.htm